PDCD1 and neoplasm: The biomarker data show that cibisatamab treatment triggered the relocalization of CD8 T cells from the periphery and/or the expansion of pre-existing CD8 T cells within the tumour, as well as increased PDCD1 levels, leading to an inflamed tumour phenotype.